Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-05-10

Study Completion Date

2008-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aerosol Cyclosporine for Prevention of Lung Rejection

NCT00268515

Lung Diseases

COMPLETED PHASE2

Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients

NCT00812786

Heart Transplant

COMPLETED PHASE4

Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation

NCT00204191

Kidney Transplantation

UNKNOWN PHASE4

Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients

NCT00170859

Heart Transplantation

COMPLETED PHASE4

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274

Graft Rejection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subcellular markers will be assessed in relationship to cellular acute rejection in de novo cardiac transplant recipients receiving either tacrolimus or cyclosporine as their primary immunosuppressant

Two parallel active arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Diseases Heart Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tacrolimus - Adult

Adults: 0.05 - 0.10 mg/ kg/ day in 2 divided doses starting within 10 days of transplant

Group Type EXPERIMENTAL

Tacrolimus

Intervention Type DRUG

Oral

Mycophenolate mofetil

Intervention Type DRUG

Intravenous and Oral

Methylprednisolone

Intervention Type DRUG

Intravenous

Prednisone

Intervention Type DRUG

Oral

Cyclosporine - Adult

Adults: 3-5 mg/ kg/ day in 2 divided doses starting within 10 days of transplant

Group Type ACTIVE_COMPARATOR

Cyclosporine

Intervention Type DRUG

Oral

Mycophenolate mofetil

Intervention Type DRUG

Intravenous and Oral

Methylprednisolone

Intervention Type DRUG

Intravenous

Prednisone

Intervention Type DRUG

Oral

Tacrolimus - Pediatric

Pediatrics: 0.05 - 0.30 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant

Group Type EXPERIMENTAL

Tacrolimus

Intervention Type DRUG

Oral

Mycophenolate mofetil

Intervention Type DRUG

Intravenous and Oral

Methylprednisolone

Intervention Type DRUG

Intravenous

Prednisone

Intervention Type DRUG

Oral

Cyclosporine - Pediatric

Pediatrics: 6 - 10 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant

Group Type ACTIVE_COMPARATOR

Cyclosporine

Intervention Type DRUG

Oral

Mycophenolate mofetil

Intervention Type DRUG

Intravenous and Oral

Methylprednisolone

Intervention Type DRUG

Intravenous

Prednisone

Intervention Type DRUG

Oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tacrolimus

Oral

Intervention Type DRUG

Cyclosporine

Oral

Intervention Type DRUG

Mycophenolate mofetil

Intravenous and Oral

Intervention Type DRUG

Methylprednisolone

Intravenous

Intervention Type DRUG

Prednisone

Oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prograf FK506 CellCept

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients (or their legal guardians) who are capable of understanding, and who have been fully informed of the purpose of the study and the risks of participation.
* Patients (or their legal guardians) who have signed and dated the Informed Consent form and are willing and able to follow the study protocol.
* Patients who are primary cadaveric heart transplant recipients.
* Males or females from birth.
* Female patients of child-bearing potential who have a current negative pregnancy test and agree to practice effective birth control, as judged by the investigator, while participating in the study. Prepubescent pediatric patients will not require pregnancy testing.
* Patients able to tolerate oral medication and who do not have a gastrointestinal condition likely to affect the absorption kinetics or metabolism of the oral study medications.

Exclusion Criteria

* Previous organ transplant recipients.
* Multi-organ transplant recipients.
* Recipients of a heart from a donor with incompatible ABO blood type.
* Patients with significant graft dysfunction and/or significant de novo infection(s) at time of randomization
* Patients with known hypersensitivity to tacrolimus, cyclosporine, mycophenolate mofetil (MMF), daclizumab, prednisone, cremophor, polysorbate 80 and/or polyoxyl 60 hydrogenated castor oil (HCO-60).
* Patients who are pregnant or lactating or planning to become pregnant prior to completion of the study.
* Patients who have consumed an investigational product in the 30 days prior to transplantation or at any time during post-transplantation follow-up.
* Patients receiving cholestyramine or colestipol.
* Patients having any one of the following at enrolment:

1. History of malignancy, not chart-documented as cured or active malignancy (with exception of eradicable non-metastatic in-situ basal cell or squamous cell carcinoma).
2. Leukopenia (white cell count \< 2500/cu mm).
3. Anemia (hemoglobin \< 80 g/L).
4. Positive test for hepatitis B surface antigen and/or hepatitis C.
5. Historical positive test for human immunodeficiency virus (HIV).
6. Serum creatinine \> 230 umol/l.
7. Continual elevation of AST and/or ALT to \>= 3X the upper limit of normal.
8. Body mass index (weight in kg/height in m2) \> 30.
* Undiagnosed diabetes mellitus as determined by 2 hour (2h) oral glucose tolerance test (OGTT) or fasting glucose test or uncontrolled diabetes mellitus at screening. In either case, the patient may be declared as no longer excluded by this criterion upon establishment of control of the diabetes through appropriate medical management.
* Blood glucose \>= 11.1 mmol/L at pre-operative assessment.
* Patients having a significant disease, substance dependency, or disability that may prevent adherence to, or understanding of, the protocol and/or the investigator's instructions.

Eligible Sex

ALL

Accepts Healthy Volunteers

No